Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary ...

Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease ...

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics ...

“During the quarter, we delivered numerous posters, presentations and publications on the potential of ATH434 as a disease modifying treatment in a variety of indications including MSA, Parkinson’s ...

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed ... at the ASCO-GI meeting at ASCO-GI Abstract, and poster at ...

How a struggling biotech company became a university ‘spin ... There, we presented a poster on the study, which was covered by several news outlets. The Theranos situation set back this type ...